



Advancements in Lung Cancer Precision Oncology Research and Treatments

Guest Editors:

Dr. Panagiotis Paliogiannis

Anatomic Pathology and
Histology Unit, Department of
Medicine, Surgery and Pharmacy,
University of Sassari, Viale San
Pietro 43, Sassari, Italy

Prof. Dr. Giuseppe Palmieri

Unit of Immuno-Oncology,
Department of Medicine, Surgery
and Pharmacy, University of
Sassari, Viale San Pietro 43,
Sassari, Italy

Dr. Francesca Colonese

Medical Oncology Unit,
Fondazione IRCCS San Gerardo
dei Tintori Hospital in Monza, Via
Giambattista Pergolesi 33, 20900
Monza, Italy

Deadline for manuscript
submissions:

30 September 2025

Message from the Guest Editors

Dear Colleagues,

Lung cancer is one of the most common malignancies and the first cause of cancer death worldwide. Significant improvements in lung cancer survival have been obtained in the last decade by introducing two novel therapeutic approaches for patients affected by non-small cell lung cancer (NSCLC), a histological subtype that includes approximately 85% of lung cancers: immunotherapy and gene-targeted therapy. These treatments are based on identifying predictive biomarkers, revolutionizing daily practice in modern pathology and medical oncology, and bridging consistent survival advantages in NSCLC patients. Currently, EGFR, KRAS, BRAF, ERBB2, ALK, ROS1, MET, RET, and NTRK genetic alterations and PD-L1 immunohistochemical expression are used to make treatment decisions, and a great number of ongoing clinical trials investigate novel molecular targets, medications, treatment combinations and protocols against lung cancer. This Special Issue aims to shed light on the most recent advancements in precision oncology research and current innovations in targeted and immunological treatments against lung cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)